vs
Side-by-side financial comparison of Bio-Techne (TECH) and WSFS FINANCIAL CORP (WSFS). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $275.3M, roughly 1.1× WSFS FINANCIAL CORP). WSFS FINANCIAL CORP runs the higher net margin — 31.5% vs 12.8%, a 18.7% gap on every dollar of revenue. On growth, WSFS FINANCIAL CORP posted the faster year-over-year revenue change (7.5% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs 1.7%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
WSFS Financial Corporation is a financial services company. Its primary subsidiary, WSFS Bank, a federal savings bank, is the largest and longest-standing locally managed bank and wealth management franchise headquartered in Delaware and the Greater Delaware Valley. WSFS operates from 115 offices, 88 of which are banking offices, located in Pennsylvania (57), Delaware (39), New Jersey (14), Florida (2), Virginia (1), and Nevada (1) and provides comprehensive financial services including comme...
TECH vs WSFS — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $295.9M | $275.3M |
| Net Profit | $38.0M | $86.8M |
| Gross Margin | 64.6% | — |
| Operating Margin | 18.4% | — |
| Net Margin | 12.8% | 31.5% |
| Revenue YoY | -6.4% | 7.5% |
| Net Profit YoY | 68.3% | 31.7% |
| EPS (diluted) | $0.24 | $1.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $275.3M | ||
| Q4 25 | $295.9M | $271.9M | ||
| Q3 25 | — | $270.5M | ||
| Q2 25 | $317.0M | $267.5M | ||
| Q1 25 | $316.2M | $256.1M | ||
| Q4 24 | $297.0M | $261.5M | ||
| Q3 24 | $289.5M | $267.7M | ||
| Q2 24 | $306.1M | $266.0M |
| Q1 26 | — | $86.8M | ||
| Q4 25 | $38.0M | $72.7M | ||
| Q3 25 | — | $76.4M | ||
| Q2 25 | $-17.7M | $72.3M | ||
| Q1 25 | $22.6M | $65.9M | ||
| Q4 24 | $34.9M | $64.2M | ||
| Q3 24 | $33.6M | $64.4M | ||
| Q2 24 | $40.6M | $69.3M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 62.7% | — | ||
| Q1 25 | 67.9% | — | ||
| Q4 24 | 65.3% | — | ||
| Q3 24 | 63.2% | — | ||
| Q2 24 | 66.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 18.4% | 35.8% | ||
| Q3 25 | — | 37.3% | ||
| Q2 25 | -7.5% | 35.7% | ||
| Q1 25 | 12.2% | 34.0% | ||
| Q4 24 | 16.0% | 32.3% | ||
| Q3 24 | 13.8% | 31.9% | ||
| Q2 24 | 15.0% | 34.0% |
| Q1 26 | — | 31.5% | ||
| Q4 25 | 12.8% | 26.7% | ||
| Q3 25 | — | 28.3% | ||
| Q2 25 | -5.6% | 27.0% | ||
| Q1 25 | 7.1% | 25.7% | ||
| Q4 24 | 11.7% | 24.6% | ||
| Q3 24 | 11.6% | 24.1% | ||
| Q2 24 | 13.3% | 26.0% |
| Q1 26 | — | $1.64 | ||
| Q4 25 | $0.24 | $1.33 | ||
| Q3 25 | — | $1.37 | ||
| Q2 25 | $-0.11 | $1.27 | ||
| Q1 25 | $0.14 | $1.12 | ||
| Q4 24 | $0.22 | $1.08 | ||
| Q3 24 | $0.21 | $1.08 | ||
| Q2 24 | $0.26 | $1.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.9M | — |
| Total DebtLower is stronger | $260.0M | — |
| Stockholders' EquityBook value | $2.0B | $2.7B |
| Total Assets | $2.5B | $22.1B |
| Debt / EquityLower = less leverage | 0.13× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $172.9M | $1.7B | ||
| Q3 25 | — | — | ||
| Q2 25 | $162.2M | — | ||
| Q1 25 | $140.7M | — | ||
| Q4 24 | $177.5M | $1.2B | ||
| Q3 24 | $187.5M | — | ||
| Q2 24 | $152.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $260.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $346.0M | — | ||
| Q1 25 | $330.0M | — | ||
| Q4 24 | $300.0M | — | ||
| Q3 24 | $300.0M | — | ||
| Q2 24 | $319.0M | — |
| Q1 26 | — | $2.7B | ||
| Q4 25 | $2.0B | $2.7B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | $1.9B | $2.7B | ||
| Q1 25 | $2.0B | $2.7B | ||
| Q4 24 | $2.1B | $2.6B | ||
| Q3 24 | $2.1B | $2.7B | ||
| Q2 24 | $2.1B | $2.5B |
| Q1 26 | — | $22.1B | ||
| Q4 25 | $2.5B | $21.3B | ||
| Q3 25 | — | $20.8B | ||
| Q2 25 | $2.6B | $20.8B | ||
| Q1 25 | $2.6B | $20.5B | ||
| Q4 24 | $2.7B | $20.8B | ||
| Q3 24 | $2.7B | $20.9B | ||
| Q2 24 | $2.7B | $20.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.13× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.16× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
WSFS
Segment breakdown not available.
